The scientists at The Scripps Research Institute (TSRI) have discovered the workings of the first promising treatment for Marburg virus, a pathogen with the same pandemic potential as Ebola virus. The research builds on previous studies showing that an antibody called MR191 can neutralize Marburg.

With a mortality rate of up to 88%, Marburg virus can rip through a community in days. In 2005, an outbreak of Marburg virus struck a pediatric ward in the country of Angola. With no treatment available, doctors struggled to help as the virus killed 329 of 374 infected patients.

For the new study, TSRI scientists created a map of the virus' structure and revealed through high-resolution imaging how MR191 targets and neutralize the virus. This antibody could finally give doctors a way to successfully treat the disease.

"This is the first antibody therapeutic found that could treat Marburg," said Erica Ollmann Saphire, a TSRI professor and senior author of the study.

"With this new structure, we can start to see how this treatment works," adds Liam King, a TSRI graduate student and first author of the study. "We have also learned new things about the virus itself that could lead to new treatments and vaccines."

The scientists used a high-resolution imaging technique called x-ray crystallography and found that MR191 neutralizes the virus by mimicking the host receptor and plugging into a spot on the viral surface called the receptor binding site. With this site occupied, the virus can no longer attach itself to human cells and spread infection.

The imaging also shows part of the architecture of a "wing" that sticks out of the side of the viral structure. The wing was particularly important for researchers to map since it appears to be one of only two known sites where protective human antibodies can bind. The wing folds around the outside of the glycoprotein spike.

Ebola and Marburg viruses use a structure called a glycan cap to shield the vulnerable receptor binding site from the human immune system, the new study reveals that MR191 can get around the glycan cap on Marburg virus— an ability scientists have not observed for any antibodies against Ebola virus.

Ollmann Saphire said, the next step is to study how known mutations in Marburg evade such antibodies and to use that information to devise second-line treatments. Soon, the team hopes to see the antibody therapeutic go into clinical trials.